Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute.

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Diabetic Foot
Interventions
BIOLOGICAL

Heberprot P

75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.

All Listed Sponsors
collaborator

Cuban Center for Genetic Engineering and Biotechnology

OTHER

lead

Dasman Diabetes Institute

OTHER

NCT03239457 - Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute. | Biotech Hunter | Biotech Hunter